MigVax

About MigVax

MigVax is a biotechnology startup focused on developing an innovative oral subunit vaccine for COVID-19. The company operates in the biopharmaceutical sector, targeting both public health organizations and private healthcare providers. MigVax's core product, MigVax 101, utilizes a chimeric protein to generate three kinds of simultaneous immunological responses: mucosal, blood-based, and cell-mediated immunity. This comprehensive approach aims to provide robust protection against the virus by activating all arms of the immune system. The vaccine's epitopes were designed using computational chemistry, focusing on neutralizing antibodies and promoting an immune response against various coronaviruses, including IBV, MERS, SARS-CoV, and SARS-CoV-2. MigVax was established in 2020 with significant investment from OurCrowd, a leading crowdfunding venture platform. The company leverages the extensive experience of its interdisciplinary research team, which has a strong background in vaccine development projects at MIGAL, a research institute in Israel. MigVax's business model involves the development and commercialization of its vaccine technology, generating revenue through licensing agreements, partnerships, and direct sales to healthcare providers and governments. The company aims to address the logistical and technical challenges associated with injectable vaccines by offering an oral alternative that is easier to distribute and administer.